Any solutions to both "minimization terminated" and "high" relative bioavailability

From: Hong-Guang Xie Date: August 21, 2008 technical Source: mail-archive.com
Dear NONMEM Users, Recently I combined six popPK studies (STDY) together as a whole and tried to re-estimate the pop PK parameters of that drug in the population with a wide range of the age and body weight. In the pooled dataset, all subjects were given with a single dose of that drug. Part of the control stream was provided as follows. Based on the prior knowledge that a two-compartment model with first-order absorption and elimination is used to describe its PK profile well, a two-compartment model was used for my meta-popPK analysis. After the NM run for the additive or proportional error model or both, the NM indicated that "*MIN*IMIZATION *T*ERMINATED DUT TO ROUNDING ERRORS (ERROR=134)" alone or in combination with "ADDITIONAL PROBLEMS OCCURED WITH THE MINIMIZATION. REGARD THE RESULTS OF THE ESTIMATION STEP CAREFULLY, AND ACCEPT THEM ONLY AFTER CHECKING THE COVARIANCE STEP PRODUCES REASONABLE OUTPUT". In addition, the typical values of the relative bioavailability (*F1*) was estimated as 5 - 8 for STDY 3 (that is, f13), 9 -14 for STDY 5 (or f15) and 0.4 - 0.53 for STDY 6 (f16). Obviously, only f16 seems to be reasonable. The drug used in the STDY 3 and 5 was given extravascularly, and thus their F1 values should be less than 1. To fix these problems, I have made many efforts but failed. For this, I would appreciate your time and suggestions. Thank you, Hong-Guang Xie ================== ............ $SUBROUTINE ADVAN4 TRANS4 $PK ETAMX = 10 SI1=0 SI2=0 SI3=0 SI4=0 SI5=0 SI6=0 IF (STDY .EQ. 1) SI1=1 ; iv IF (STDY .EQ. 2) SI2=1 ; iv IF (STDY .EQ. 3) SI3=1 ; epidural IF (STDY .EQ. 4) SI4=1 ; iv IF (STDY .EQ. 5) SI5=1 ; rectal IF (STDY .EQ. 6) SI6=1 ; oral IV = SI1+SI2+SI4 ;intravascular dosing ;APPARENT CLEARANCE TVCL=popcl PPVCL=bsvcl IF (ABS(PPVCL) .GE. ETAMX) EXIT 1 10 CL=TVCL*EXP(PPVCL) ;CENTRAL VOLUME OF DISTRIBUTION TVV2=popv2 PPVV2=bsvv2 IF (ABS(PPVV2) .GE. ETAMX) EXIT 1 20 V2=TVV2*EXP(PPVV2) ;INTERCOMPARTMENTAL CLEARANCE TVQ=popq PPVQ=bsvq IF (ABS(PPVQ) .GE. ETAMX) EXIT 1 30 Q=TVQ*EXP(PPVQ) ;PERIPHERAL VOLUME OF DISTRIBUTION TVV3=popv3 PPVV3=bsvv3 IF (ABS(PPVV3) .GE. ETAMX) EXIT 1 40 V3=TVV3*EXP(PPVV3) ;FIRST ORDER ABSORPTION RATE CONSTANT TVKA=SI3*ka3+SI5*ka5+SI6*ka6 PPVKA=bsvka IF (ABS(PPVKA) .GE. ETAMX) EXIT 1 50 KA=TVKA*EXP(PPVKA) ;LAG TIME TVLAG=SI3*lag3+SI5*lag5+SI6*lag6 PPVLAG=bsvlag IF (ABS(PPVLAG) .GE. ETAMX) EXIT 1 60 ALAG1=TVLAG*EXP(PPVLAG) ;BIOAVAILABILITY (BA) TVF1=SI3*f13+SI5*f15+SI6*f16 PPVF1=bsvf1 IF (ABS(PPVF1) .GE. ETAMX) EXIT 1 70 BA=TVF1*EXP(PPVF1) IF (IV .GE. 1) THEN F1=1 ELSE F1=BA ENDIF ;ZERO ORDER ABSORPTION DURATION TVD2=SI1*d21+SI2*d22+SI4*d24 PPVD2=bsvd2 IF (ABS(PPVD2) .GE. ETAMX) EXIT 1 80 D2=TVD2*EXP(PPVD2) RMIN=AMT/(60*D2) ;mcg/minute ; SCALING FOR CENTRAL COMPARTMENT (I.E., CONCENTRATION COMPARTMENT) S2=V2 ; DOSE IN MCG, CONCENTRATION IN NG/ML=MCG/L $ERROR IPRED = F IF (MDV .EQ. 0) THEN W = SQRT(add**2 + F*F*prop**2) ELSE W = 1 ENDIF IRES=DV-IPRED IF (W .EQ. 0) THEN IWRES=IRES ELSE IWRES=IRES/W ENDIF Y=F+W*eps1*EXP(bsvres) $THETA (0,11.5) ;popcl (0,24.1) ;popv2 (0,12.9) ;popq (0,8.22) ;popv3 (0,0.14) ;ka3 (0,0.109) ;ka5 (0,0.397) ;ka6 (0 FIX) ;lag3 (0 FIX) ;lag5 (0 FIX) ;lag6 (0,4.93) ;f13 (0,9.19) ;f15 (0,0.523) ;f16 (0,0.00072) ;d21 (0,0.00007) ;d22 (0,0.00003) ;d24 (0, 0.01) ;add (0, 0.05) ;prop $OMEGA 0.828 ;bsvcl $OMEGA 1.63 ;bsvv2 $OMEGA 0 FIX ;bsvq $OMEGA 0 FIX ;bsvv3 $OMEGA 0 FIX ;bsvka $OMEGA 0 FIX ;bsvlag $OMEGA 0 FIX ;bsvf1 $OMEGA 0 FIX ;bsvd2 $OMEGA 0 FIX ;bsvres $SIGMA 1. FIX ; eps1 $ESTIMATION NOABORT MAXEVAL=9999 POSTHOC PRINT=5 SIGDIGITS=3 MSFO= METHOD=CONDITIONAL INTERACTION ;$COV PRINT=E $TABLE ID STDY TIME DV IPRED AMT MDV CMT CL V2 Q V3 KA ALAG1 F1 D2 RATE RMIN ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 IWRES IRES WT BWT AGEY AGED GAGE NOPRINT ONEHEADER FILE= ===================================================================================
Aug 21, 2008 Hong-Guang Xie Any solutions to both "minimization terminated" and "high" relative bioavailability
Aug 21, 2008 Nick Holford Re: Any solutions to both "minimization terminated" and "high" relative bioavailability
Aug 21, 2008 Mark Sale RE: Any solutions to both "minimization terminated" and "high" relative bioavailability
Aug 22, 2008 Hong-Guang Xie Re: Any solutions to both "minimization terminated" and "high" relative bioavailability